Perrigo Completes €305.6M Sale of Dermacosmetics Business, Bolstering Balance Sheet
PRGO sits 28% above its 52-week low of $9.225.
Summary
Perrigo completed the sale of its Dermacosmetics business for €305.6 million upfront, a move expected to reduce debt and streamline its portfolio.
Key Events · M&A and Partnerships · PRGO
-
Divestiture Completed
Perrigo completed the sale of its Dermacosmetics branded business to Karo Healthcare, as previously agreed on July 13, 2025.
-
Significant Cash Proceeds
The company received €305.6 million in upfront cash, including net working capital adjustments, with potential for an additional €27.0 million in contingent consideration over three years.
-
Strategic Debt Reduction
Proceeds from the sale will primarily be used to reduce debt, enhancing financial flexibility and strengthening the balance sheet, a critical step following a $1.43 billion net loss in 2025.
-
Portfolio Streamlining
The divestiture of the Dermacosmetics business, which generated approximately €120 million in net sales in 2025, aligns with Perrigo's 'Three-S plan' to stabilize, streamline, and strengthen the company.
Analysis · PRGO · Life Sciences
Perrigo has finalized the divestiture of its Dermacosmetics branded business, receiving €305.6 million in upfront cash. This strategic move, which follows the company's recent significant net loss and goodwill impairment disclosed in its 10-K, is aimed at streamlining its portfolio, focusing on core categories, and primarily reducing debt. The transaction enhances financial flexibility and strengthens the balance sheet, addressing a critical need highlighted by the company's financial baseline.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRGO was trading at $11.84 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.